Weight Changes and their Associations with Demographic and Clinical Characteristics in Risperidone Maintenance Treatment for Schizophrenia

Abstract

Objective: This study aimed to characterize weight changes in schizophrenia patients taking risperidone as part of a randomized, controlled, open-label clinical trial.

Methods: A total of 374 patients with schizophrenia who had been clinically stabilized following an acute episode were randomly assigned to a ‘no-dose-reduction’ group (initial optimal therapeutic doses continued throughout the study), a ‘4-week group’ (initial optimal therapeutic doses continued for 4 weeks followed by a half dose reduction that was maintained until the end of the study) or a ‘26-week group’ (initial optimal therapeutic doses continued for 26 weeks followed by a half dose reduction until the end of the study). Participants were assessed monthly using standardized assessment instruments during the first 6 months, and then every 2 months until the last recruited patient completed the 1-year follow-up. Weight gain was defined as gaining at least 7% of initial body weight, weight loss as losing at least 7% of initial body weight. A BMI <18.5 kg m⁻² was defined as underweight, 18.5–24.9 kg m⁻² as normal range, and ≥25 kg m⁻² as overweight or obese.

Results: At the end of follow-up, of the patients who started within the underweight range (n=22), 77.3% gained weight, whereas 4.5% lost weight. The corresponding figures were 39.6% and 4.8% in patients who started at normal weight (n=273), respectively, and 17.7% and 17.7% in patients who started at overweight (n=79), respectively. At the same time, 59.1% of the patients who started at underweight range went into the normal weight and 13.6% into the overweight/obese range, respectively, while 24.5% of those who started at normal weight went into the overweight/obese range, and 1.1% into underweight range, respectively; 20.3% of those who started at overweight range went into normal weight at the end of the follow-up. Multiple logistic regression analyses revealed that being underweight or normal weight at study entry predicted weight gain compared to being overweight, whereas being overweight at entry was associated with a higher likelihood of weight loss compared to being normal weight. No correlation was found between weight change and dose reduction.

Conclusions: Weight change is a common, long-term, but heterogeneous side effect in risperidone maintenance treatment for stable schizophrenia patients. Special attention should be paid to fluctuations in weight that may occur throughout the course of treatment with risperidone.

References

• 1 Herva A, Laitinen J, Miettunen J. et al . Obesity and depression: results from the longitudinal Northern Finland 1966 Birth Cohort Study.  Int J Obes. 2006;  30 520-527
• 2 McEvoy JP, Meyer JM, Goff DC. et al . Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III.  Schizophr Res. 2005;  80 19-32
• 3 Mukherjee S, Decina P, Bocola V. et al . Diabetes mellitus in schizophrenic patients.  Compr Psychiatry. 1996;  37 68-73
• 4 Robinson DG, Woerner MG, Delman HM. et al . Pharmacological treatments for first-episode schizophrenia.  Schizophr Bull. 2005;  31 705-722
• 5 Weiss F. Group psychotherapy with obese disordered-eating adults with body-image disturbances: an integrated model.  Am J Psychother. 2004;  58 281-303
• 6 Perkins DO. Predictors of noncompliance in patients with schizophrenia.  J Clin Psychiatry. 2002;  63 1121-1128
• 7 Wirshing DA, Wirshing WC, Kysar L. et al . Novel antipsychotics: comparison of weight gain liabilities.  J Clin Psychiatry. 1999;  60 358-363
• 8 Allison DB, Mackell JA, McDonnell DD. The impact of weight gain on quality of life among persons with schizophrenia.  Psychiatr Serv. 2003;  54 565-567
• 9 Bobes J, Rejas J, Garcia-Garcia M. et al . Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.  Schizophr Res. 2003;  62 77-88
• 10 Basile VS, Masellis M, McIntyre RS. et al . Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle.  J Clin Psychiatry. 2001;  62 (S 23) 45-66
• 11 Park YM, Chung YC, Lee SH. et al . Weight gain associated with the alpha2a-adrenergic receptor-1,291 C/G polymorphism and olanzapine treatment.  Am J Med Genet B Neuropsychiatr Genet. 2006;  141B 394-397
• 12 Rege S. Antipsychotic induced weight gain in schizophrenia: mechanisms and management.  Aust N Z J Psychiatry. 2008;  42 369-381
• 13 Reynolds GP, Hill MJ, Kirk SL. The 5-HT2C receptor and antipsychotic-induced weight gain – mechanisms and genetics.  J Psychopharmacol. 2006;  20 15-18
• 14 Yang LH, Chen TM, Yu ST. et al . Olanzapine induces SREBP-1-related adipogenesis in 3T3-L1 cells.  Pharmacol Res. 2007;  56 202-208
• 15 Kelly DL, Conley RR, Carpenter WT. First-episode schizophrenia: a focus on pharmacological treatment and safety considerations.  Drugs. 2005;  65 1113-1138
• 16 Allison DB, Mentore JL, Heo M. et al . Antipsychotic-induced weight gain: a comprehensive research synthesis.  Am J Psychiatry. 1999;  156 1686-1696
• 17 Wetterling T. Bodyweight gain with atypical antipsychotics. A comparative review.  Drug Saf. 2001;  24 59-73
• 18 Bai YM, Chen JY, Chen TT. et al . Weight gain with clozapine: 8-year cohort naturalistic study among hospitalized Chinese schizophrenia patients.  Schizophr Res. 2009;  108 122-126
• 19 Lipkovich I, Jacobson JG, Hardy TA. et al . Early evaluation of patient risk for substantial weight gain during olanzapine treatment for schizophrenia, schizophreniform, or schizoaffective disorder.  BMC Psychiatry. 2008;  8 78
• 20 Sussman N. Review of atypical antipsychotics and weight gain.  J Clin Psychiatry. 2001;  62 (S 23) 5-12
• 21 Lee E, Leung CM, Wong E. Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone.  J Clin Psychiatry. 2004;  65 864-866
• 22 de Leon J, Diaz FJ, Josiassen RC. et al . Weight gain during a double-blind multidosage clozapine study.  J Clin Psychopharmacol. 2007;  27 22-27
• 23 Haas M, Eerdekens M, Kushner S. et al . Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study.  Br J Psychiatry. 2009;  194 158-164
• 24 Wang CY, Xiang YT, Cai ZJ. et al . Risperidone maintenance treatment in schizophrenia: a randomized, controlled trial.  Am J Psychiatry. 2010;  167 676-685
• 25 Zhang MY. Chinese Version of Brief Psychiatric Rating Scale (in Chinese), in Handbook of Scales for Behavioral Medicine.. Edited by Zhang ZJ. Jining, Chinese Journal of Behavioral Medical Science press; 2001: 140-142
• 26 Chinese Medical Association . Guideline for the Prevention and Treatment of Schizophrenia in China.  Beijing, Chinese Medical Association 2003; 
• 27 Kinon BJ, Kaiser CJ, Ahmed S. et al . Association between early and rapid weight gain and change in weight over one year of olanzapine therapy in patients with schizophrenia and related disorders.  J Clin Psychopharmacol. 2005;  25 255-258
• 28 Tollefson GD, Beasley Jr CM, Tran PV. et al . Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.  Am J Psychiatry. 1997;  154 457-465
• 29 Csernansky JG, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.  N Engl J Med. 2002;  346 16-22
• 30 Overall JE, Beller SA. The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research: I. Factor structure on an inpatient unit.  J Gerontol. 1984;  39 187-193
• 31 Shen YC. Schizophrenia, in Psychiatry.. Edited by Shen YC. Beijing, Peopleâs medical publishing house; 2001: 393-416
• 32 Henderson DC, Cagliero E, Gray C. et al . Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study.  Am J Psychiatry. 2000;  157 975-981
• 33 Parsons B, Allison DB, Loebel A. et al . Weight effects associated with antipsychotics: a comprehensive database analysis.  Schizophr Res. 2009;  110 103-110
• 34 Basson BR, Kinon BJ, Taylor CC. et al . Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.  J Clin Psychiatry. 2001;  62 231-238
• 35 Purdon SE, Jones BD, Stip E. et al . Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.  Arch Gen Psychiatry. 2000;  57 249-258
• 36 Tran PV, Hamilton SH, Kuntz AJ. et al . Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.  J Clin Psychopharmacol. 1997;  17 407-418
• 37 Safer DJ. A comparison of risperidone-induced weight gain across the age span.  J Clin Psychopharmacol. 2004;  24 429-436
• 38 Kennedy JS, Bymaster FP, Schuh L. et al . A current review of olanzapineâs safety in the geriatric patient: from pre-clinical pharmacology to clinical data.  Int J Geriatr Psychiatry. 2001;  16 (S 01) S33-S61
• 39 Gentile S. Long-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis.  Drug Saf. 2006;  29 303-319
• 40 Lane HY, Chang YC, Cheng YC. et al . Effects of patient demographics, risperidone dosage, and clinical outcome on body weight in acutely exacerbated schizophrenia.  J Clin Psychiatry. 2003;  64 316-320
• 41 Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology.  Schizophr Res. 2003;  59 19-27
• 42 Williams R. Optimal dosing with risperidone: updated recommendations.  J Clin Psychiatry. 2001;  62 282-289

Correspondence